Basic class	Proposed 1996 quotas
Narmathadana	7
Normethadone	7
Normorphine	7
Psilocybin	2
Psilocyn	2
Tetrahydrocannibinols	55,100
Schedule II:	
Alfentanil	8,500
Amobarbital	15
Amphetamine	1,300,100
Cocaine	550,040
Codeine (for sale)	58,395,000
Codeine (for conversion)	16,632,000
Desoxyephedrine, 1,000,000	10,032,000
grams of	
levodesoxyephedrine for	
use in a noncontrolled,	
nonprescription product	
and 44 kg for methamphet-	
amine	1,044,000
Dextropropoxyphene	118,066,000
Dihydrocodeine	60,000
Diphenoxylate	1,063,000
Ecgonine (for conversion)	650,100
Ethylmorphine	12
Contant	
Fentanyl	120,100
Hydrocodone (for sale)	8,880,000
Hydrocodone (for conversion)	2,800,000
Hydromorphone	448,000
Isomethadone	12
Levo-alpha-acetylmethadol	200,000
Levorphanol	14,300
Meperidine	10,822,000
Methadone	4,551,000
Methadone (for conversion)	364,000
Methadone Intermediate (for	
conversion)	5,534,000
Methamphetamine (for con-	
version)	723,000
Methylphenidate	10,291,000
Morphine (for sale)	12,450,000
Morphine (for conversion)	76,735,000
Noroxymorphone (for sale)	2,000
Noroxymorphone (for conver-	2,000
sion)	2,406,000
Opium	1,226,000
Oxycodone (for sale)	5,571,000
Oxycodone (for conversion)	37,300
Oxymorphone	11,200
Pentobarbital	15,100,000
Phencyclidine	40
Phenylacetone (for conver-	
sion)	5,280,000
1-Phenylcyclohexylamine	10
1-	
Piperidinocyclohexanecarb-	
onitrile	12
Secobarbital	400,000
Sufentanil	1,000
Thebaine	9,217,000

The Deputy Administrator further proposes that aggregate production quotas for all other Schedules I and II controlled substances included in §§ 1308.11 and 1308.12 of title 21 of the Code of Federal Regulations be established at zero.

All interested persons are invited to submit their comments and objections in writing regarding this proposal. A person may object to or comment on the proposal relating to any of the abovementioned substances without filing comments or objections regarding the others. If a person believes that one or more of these issues warrant a hearing, the individual should so state and summarize the reasons for this belief.

In the event that comments or objections to this proposal raise one or more issues which the Deputy Administrator finds warrant a hearing, the Deputy Administrator shall order a public hearing by notice in the **Federal Register**, summarizing the issues to be heard and setting the time for the hearing.

The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 12612, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

The Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601, et seq. The establishment of annual aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Deputy Administrator has determined that this action does not require a regulatory flexibility analysis.

Dated: July 19, 1995.

Stephen H. Greene,

Deputy Administrator.
[FR Doc. 95–18407 Filed 7–26–95; 8:45 am]
BILLING CODE 4410–09–M

Manufacturer of Controlled Substances; Registration

By Notice dated May 30, 1995, and published in the **Federal Register** on June 8, 1995 (60 FR 30318), Research Triangle Institute, Kenneth H. Davis, Jr., Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle Park, North Carolina 27709, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Marihuana (7360)	I
Cocaine (9041)	II

No comments or objections have been received. Therefore, pursuant to section 303 of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and Title 21, Code of Federal Regulations, § 1301.54(e), the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: July 19, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95–18408 Filed 7–26–95; 8:45 am]

Importer of Controlled Substances; Registration

By Notice dated May 30, 1995, and published in the Federal Register on June 8, 1995, (60 FR 30319), Research Triangle Institute, Kenneth H. Davis, Jr., Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle Park, North Carolina 27709, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed below:

Drug	Schedule
Marihuana (7360)	I
Cocaine (9041)	II

No comments or objections have been received. Therefore, pursuant to section 1008(a) of the Controlled Substances Import and Export Act and in accordance with title 21, Code of Federal Regulations, § 1311.42, the above firm is granted registration as an importer of the basic classes of controlled substances listed above.

Dated: July 19, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95–18409 Filed 7–26–95; 8:45 am] BILLING CODE 4410–09–M